Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Morschhauser

Showing results (21-30 of 42) with videos related to

Pageof 5
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2000
Feasibility of tandem autologous stem-cell transplantation (ASCT) in induction failure or very unfavorable (UF) relapse from Hodgkin's disease (HD). SFGM/GELA Study GroupP Brice, M Divine, D Simon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2000
Evaluation of minimal residual disease using reverse-transcription polymerase chain reaction in t(8;21) acute myeloid leukemia: a multicenter study of 51 patientsF Morschhauser, J M Cayuela, S Martini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2004
Prognostic factors in patients with aggressive non-Hodgkin's lymphoma treated by front-line autotransplantation after complete remission: a cohort study by the Groupe d'Etude des Lymphomes de l'AdulteN Mounier, C Gisselbrecht, J Brière, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 20, 2004
All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA)N Mounier, C Gisselbrecht, J Brière, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 23, 2017
Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphomaP J Bröckelmann, H Müller, O Casasnovas, et al.
The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of|January 30, 2013
Comparisons of dosimetric approaches for fractionated radioimmunotherapy of non-Hodgkin lymphomaL Ferrer, E Malek, C Bodet-Milin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 7, 2012
A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphomaF Morschhauser, C Recher, N Milpied, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 12, 2012
Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-upP Colombat, N Brousse, G Salles, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2015
Utility of ¹⁸fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphomaS Horwitz, B Coiffier, F Foss, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2005
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'AdulteP Feugier, A Van Hoof, C Sebban, et al.
Pageof 5

Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2000
Feasibility of tandem autologous stem-cell transplantation (ASCT) in induction failure or very unfavorable (UF) relapse from Hodgkin's disease (HD). SFGM/GELA Study GroupP Brice, M Divine, D Simon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2000
Evaluation of minimal residual disease using reverse-transcription polymerase chain reaction in t(8;21) acute myeloid leukemia: a multicenter study of 51 patientsF Morschhauser, J M Cayuela, S Martini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2004
Prognostic factors in patients with aggressive non-Hodgkin's lymphoma treated by front-line autotransplantation after complete remission: a cohort study by the Groupe d'Etude des Lymphomes de l'AdulteN Mounier, C Gisselbrecht, J Brière, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 20, 2004
All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA)N Mounier, C Gisselbrecht, J Brière, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 23, 2017
Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphomaP J Bröckelmann, H Müller, O Casasnovas, et al.
The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of|January 30, 2013
Comparisons of dosimetric approaches for fractionated radioimmunotherapy of non-Hodgkin lymphomaL Ferrer, E Malek, C Bodet-Milin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 7, 2012
A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphomaF Morschhauser, C Recher, N Milpied, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 12, 2012
Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-upP Colombat, N Brousse, G Salles, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2015
Utility of ¹⁸fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphomaS Horwitz, B Coiffier, F Foss, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2005
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'AdulteP Feugier, A Van Hoof, C Sebban, et al.
Pageof 5